Evidence Navigator: Cholecystectomy

Systematic literature review & meta-analysis as of April 15, 2024



Purpose

The Evidence Navigator is a slide presentation representing a summary of the meta-analysis of the highest level of evidence available specific to a given procedure and published as of a particular date. It is created by the Global Evidence Management team within Global Access, Value and Economics (GAVE). It includes information that is available in the public domain. It is a systematic review and meta-analysis of the peer-reviewed literature based on a timeframe within which a literature search has been conducted according to a set of concise inclusion and exclusion criteria. The results of the meta-analysis are presented in the form of forest plots summarized for each outcome according to a comparator and surgical approach of interest. The summary results are reflective of a specific period in time and are subject to change with increasing literature. All of the robotic-assisted surgery procedures mentioned within the Evidence Navigator were performed using a da Vinci[®] surgical system.

Statistical analysis

All summary measures are shown as odds ratios, risk ratios or risk differences when describing binary outcomes, or as weighted mean differences or standardized mean differences when describing continuous outcomes. Weighting is based on the study sample size and variability of the outcome. A random effect model is used if heterogeneity is statistically significant, otherwise a fixed effect model is used. The Mantel Haenszel summary statistic is used for the overall results. The meta-analysis is performed with RevMan 5.4 (Review Manager, Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) or R software (R Foundation for Statistical Computing, Vienna, Austria.URL https://www.R-project.org/).

Interpretation notes

When the effect size is measured as a standardized mean difference (SMD), or a risk difference (RD), it is not possible to provide a quantitative conclusion. In such cases, a qualitative conclusion is given with reference to its statistical significance. In some instances, studies may contain some overlapping patient populations. A redundancy check is performed in order to minimize this overlap and bias due to over-reporting.

INTUÎTIVE

Glossary

MD	mean difference
OR	odds ratio
RCT	randomized controlled trial
НТА	health technology assessment
LOE	level of evidence
Lap	laparoscopic surgery
RAS	robotic-assisted surgery

weighted mean difference
risk difference
standardized mean difference
95% confidence interval
test statistic for heterogeneity
estimated blood loss
length of hospital stay

Evidence Navigator: Cholecystectomy Summary Slides

Systematic literature review & meta-analysis as of April 15, 2024





WHAT DOES THE LITERATURE SHOW? Systematic literature review: Da Vinci robotic-assisted cholecystectomy

Inclusion criteria

Robotic-assisted cholecystectomy performed with a da Vinci surgical system

January 1, 2010 - April 15, 2024

Level of Evidence 1b, 2b, 2c, 3b

RCT, large database, prospective and retrospective cohort studies (with n≥20 in each cohort)

Exclusion criteria

Not in English

Paper reports on a pediatric population

Publication is an HTA that was not published in a peer-reviewed journal

Alternate technique/approach (e.g. single-port)

No stratified analysis by study arm

Cholecystectomy data mixed with other procedures or benign/cancer data mixed

Original research study does not provide quantitative results for outcomes of interest

Original research publication includes redundant patient population and similar conclusions

31 publications including:





(ฃฃ

WHAT DOES THE LITERATURE SHOW?

Systematic literature review key points:

Robotic-assisted vs. laparoscopic cholecystectomy

Favors robotic-assisted

- Conversions by **49%**
- Estimated blood loss by 7.65 mL

Comparable outcomes

- \approx Blood transfusion
- \approx Bile duct leak
- \approx Bile duct injury
- \approx Bile duct obstruction
- \approx Surgical site infection
- \approx Length of hospital stay
- \approx 30-day postoperative complications
- \approx 30-day readmissions
- \approx 30-day reoperations
- \approx 30-day mortality

Favors laparoscopic

U Operative time by **9.81 minutes**

Data collected: April 15, 2024



"T

WHAT DOES THE LITERATURE SHOW? Systematic literature review key points:

Robotic-assisted vs. open* cholecystectomy

Favors robotic-assisted

- Surgical site infections by 72%
- Blood transfusion by **60%**
- Length of stay by **3.5 days**
- 30-day postoperative complications by 45%
- ↓ 30-day mortality by **55%**

Comparable outcomes

- \approx Bile duct injury
- \approx 30-day readmissions
- \approx 30-day reoperations



Data collected:: April 15, 2024

*Limited data available on patients who underwent open surgery

P

WHAT DOES THE LITERATURE SHOW?

Systematic literature review key points:

Robotic-assisted vs. laparoscopic cholecystectomy

Elective vs emergent / urgent

Elective (7 studies)

- Conversions by **89%**
- ↓ Estimated blood loss by **14.3 mL**
- ↓ 30-day readmissions by **52%**
- \approx Bile duct injury
- \approx Bile duct leak
- \approx 30-day postoperative complication
- ≈ Length of stay
- ↑ Operative time by **10.37 minutes**

Emergent / Urgent (7 studies)

- Conversions by **43%**
- Estimated blood loss by **10.6 mL**
- \approx Blood transfusion
- ≈ Operative time
- ≈ Length of stay
- ≈ Bile duct injury
- ≈ Surgical site infection
- \approx 30-day postoperative complications
- \approx 30-day readmissions
- ≈ 30-day reoperations
- \approx 30-day mortality

*Limited data available on all the other outcomes amongst patients who underwent elective or emergent/urgent cholecystectomy

Significant difference favoring robotic-assisted surgery

No significant difference; comparable outcomes

Significant difference favoring laparoscopic surgery

Data collected: April 15, 2024

Evidence Navigator: Cholecystectomy Technical Slides

Systematic literature review & meta-analysis as of April 15, 2024



Cholecystectomy: Literature search methods

as of April 15, 2024

Monthly searches were conducted in PubMed, Scopus and Embase.

All citations were exported into a reference management system. Duplications were removed. Titles, abstracts and keywords were reviewed for literature review inclusion by Global Evidence Management team.

All robotic-assisted right colectomies performed with da Vinci® surgical systems. Publications were identified according to inclusion and exclusion criteria described.

Meta-analysis was performed using R software.

31 publications

135,710 patients who underwent RAS

6,172,677 patients who underwent laparoscopic surgery

499,544 patients who underwent open surgery

Level of evidence

15 15

- 2b Prospective cohort studies
- 2c Database studies

■ 3b - Retrospective cohort studies

Criteria phase Identification phase		Details		
		All robotics publications (library generated from monthly search process) N=45,378 library size at the time of search April 15, 2024		
Inc 1.	clusion criteria Robotic-assisted cholecystectomy procedure	Robotic cholecystectomy N = 424 (excluded N = 44,954)		
2.	Year ≥ 2010	Articles published ≥ 2010 N = 378 (excluded N = 46)		
3.	LOE = 1b, 2b, 2c, 3b	Articles with LOE= 1b, 2b, 2c N = 99 (excluded N = 279)		
4.	Study is an RCT, prospective or retrospective study or large database study with comparative cohorts (robotic- assisted vs lap and/or open surgery) and sample size N≥20	Comparator cohorts N = 70 (excluded N = 29)		
Ex	clusion criteria	N = 39 excluded publications:		
1.	Not in English	N = 1 (EC#1)		
2.	Paper reports on a pediatric population	N = 2 (EC#2)		
3.	Publication is an HTA that was not published in a	N = 0 (EC#3)		
4	peer-reviewed journal	N = 29 (EC#4)		
4. 5	Alternate technique/approach (e.g., single-port)	N = 1 (EC#5)		
5.	from robotic, laparoscopic, and/or open cohorts)	N =1 (EC#6)		
6.	Cholecystectomy data mixed with another procedure/s	N = 4 (EC#7)		
7.	Original research study does not provide quantitative results for the outcomes of interest	N = 1 (EC#8)		
8.	Original research publication includes redundant patient population and similar conclusions			

Cholecystectomy publications: N = 31

Robotic-assisted vs. laparoscopic cholecystectomy Summary as of April 15, 2024

Significant difference favoring robotic-assisted surgery

comparable outcomes laparoscopic surgery

Compared to laparoscopic cholecystectomy, the evidence for robotic-assisted cholecystectomy using the da Vinci surgical system demonstrates:

- Significantly less estimated blood loss by an average of 7.65 mL
- Comparable length of hospital stay
- Significantly longer operative time by an average of 9.81 minutes

Weighted Mean Difference (WMD) 95% Cl	Outcome	Robotic-assisted, n	Laparoscopic, n	Effect Size WMD, 95%CI	P-value
	Cholecystectomy Continue	ous Variables (to <i>l</i>	April 15, 2024)		
	EBL, mL ^{3,8,9,10,30,31} Subtotal Random, Heterogeneity: p<0.01; I ² =7	1228 70%	1104	-7.65 [-13.74 ; -1.56]	p=0.01
ł	LOS, days 23,4,5,6,7,8,9,10,11,12,13,14,15 Subtotal Random, Heterogeneity: p<0.01; l ² =5	;,16,20,21,22,24,25,28,29,30,31 65771 98%	655164	-0.19 [-0.47 ; 0.09]	p=0.18
-+	Operative Time, min 3,5,7,8,9,11,7 Subtotal Random, Heterogeneity: p=0; l ² =96%	12,14,15,20,28,29,20,31 14918 6	60437	9.81 [4.41 ; 15.2]	p<0.01
-10 -5 0 5 10					

Robotic-assisted vs. laparoscopic cholecystectomy Summary as of April 15, 2024

0.5

robotic-assisted

Favors

0.7

1.5

laparoscopic

Favors

2

Odds Ratio (OR)

95% CI

Significant difference favoring robotic-assisted surgery comparable outcomes laparoscopic surgery

Compared to laparoscopic cholecystectomy, the evidence for **robotic-assisted cholecystectomy using the da Vinci surgical system** demonstrates:

- 49% less likely to have a conversion to open surgery
- Comparable bile duct obstruction rate
- Comparable surgical site infection rate
- Comparable mortality rate within 30-days of surgery
- Comparable blood transfusions rate
- Comparable reoperations rate within 30-days of surgery
- Comparable readmissions rate within 30-days of surgery
- Comparable postoperative complications rate within 30-days of surgery
- Comparable bile duct injury rate
- Comparable bile duct leak rate

Outcome	Robotic- assisted, n	Laparoscopic, n	Effect size OR 95% Cl	P-value
Cholecystectomy Binary	/ariables (to Apr	il 15, 2024)		
Conversions, n 3,4,5,7,8,9,10,11,12,1	6,17,19,22,26,28,30,31			
Subtotal Random, Heterogeneity: p<0.0 ²	44158 1; I²=90%	830372	OR: 0.51 [0.33 ; 0.79]	p<0.01
Bile Duct Obstruction, n ^{3,5,16,3}	1			
Subtotal Fixed, Heterogeneity: p<0.01.18	11392 3; I²=39%	41964	OR: 0.83 [0.52 ; 1.35]	p=0.46
Surgical Site Infection, n 4,5,8,9	,12			
Subtotal Fixed, Heterogeneity: p=0.62; l ²	14070 ≌=0%	38036	OR: 0.97 [0.76; 1.24]	p=0.80
Mortality 30-day, n 1,3,4,5,8,12,13,2	5			
Subtotal Fixed, Heterogeneity: p=0.63; l ²	60078 =65%	3301695	OR: 1.01 [0.88 ; 1.15]	p=0.93
Blood transfusions, n 4,5,8,12,16,	30			
Subtotal Fixed, Heterogeneity: p=0.61; l ²	15065 =0%	69002	OR: 1.03 [0.88 ; 1.21]	p=0.71
Reoperations 30-day, n 4,5,7,8,3	D			
Subtotal Fixed, Heterogeneity p=0.87; I ²	10911 =0%	10887	OR: 1.04 [0.81 ; 1.34]	p=0.75
Readmissions 30-day. n 3,4,5,6,	8,9,12,16,20,25,26,28,30,31			
Subtotal Fixed, Heterogeneity: p=0.03: I ²	18056 ≔47%	162332	OR: 1.07 [0.98 ; 1.17]	p=0.12
Postoperative Complications	30-day, n 1,2,3,5,12,13	16,17,18,24,25,31		
Subtotal	102630	4572137	OR: 1.13 [0.97 ; 1.31]	p=0.12
Random, Heterogeneity: p<0.07	l; l²=97%			
Bile Duct Injury, n 3,5,7,9,10,11,12,1	6,18,30			
Subtotal	40459	1069928	OR: 1.39 [0.66 ; 2.93]	p=0.39
Random, Heterogeneity p<0.01	; I²=86%			
Bile Duct Leak, n 3,8,30,31				
Subtotal	532	746	OR: 3.00 [0.60 ; 14.96]	p=0.18
Fixed. Heterogeneity p=0.80 [.] I ²	=0%			

INTUÎTIVE

MAT06485 V1 Global; excluding KR 12/2024 13 of 20

Robotic-assisted vs. open cholecystectomy Summary as of April 15, 2024

Significant difference favoring No significant difference; Significant difference favoring robotic-assisted surgery

comparable outcomes open surgery

Compared to open cholecystectomy, the evidence for robotic-assisted	Weighted Mean Difference (WMD) 95% Cl	Outcome	Robotic- assisted, n	Open, n	Effect Size WMD, 95%CI	P-value
cholecystectomy using the da Vinci surgical system demonstrates:		Cholecystectomy Co	ontinuous Variables	(to April 15, 202	24)	
• Significantly shorter hospital length of stay by an average of 3.51 days	-+	LOS, days ^{4,5} Subtotal Random, Heterogene	2462 eity: p<0.01; l²=95%	2461	-3.51 [-4.49 ; -2.53]	p<0.01
	-4 -2 0 2 4 Favors Favors robotic-assisted open					

Robotic-assisted vs. open cholecystectomy Summary as of April 15, 2024

Odds Ratio (OR) 95% CI

+

0.5

2

Favors open

5

0.1

0.2

Favors robotic-assisted

 Significant difference favoring robotic-assisted surgery
No significant difference;
Significant difference favoring comparable outcomes
open surgery

Compared to open cholecystectomy, the evidence for **robotic-assisted cholecystectomy using the da Vinci surgical system** demonstrates:

- 72% less likely to experience surgical site infections
- 60% less likely to experience blood transfusion
- 55% less likely to experience mortality within 30days of surgery
- 45% less likely to experience postoperative complications within 30-days of surgery
- · Comparable bile duct injury rate
- Comparable readmissions within 30-days of surgery
- Comparable reoperations within 30-days of surgery

Outcome	Robotic- assisted, n	Open, n	Effect size OR 95% CI	P-value		
Cholecystectomy Binary Variables (to April15, 2024)						
Surgical Site Infection, n 4	5					
Subtotal	2737	2737	OR: 0.28 [0.20; 0.40]	p<0.01		
Fixed, Heterogeneity: p=0.65	5; I²=0%					
Blood Transfusion, n ^{4,18}						
Subtotal	2737	2737	OR: 0.40 [0.22 ; 0.74]	p<0.01		
Random, Heterogeneity: p=0).10; I²=63%					
Mortality 30-day, n 4,5						
Subtotal	2737	2737	OR: 0.45 [0.34 ; 0.60]	p<0.01		
Fixed, Heterogeneity: p=0.19); I²=41%					
Postoperative Complicatio	ns 30-day, n ^{5,18}					
Subtotal	27138	266735	OR: 0.55 [0.46 : 0.66]	p<0.01		
Random, Heterogeneity: p=0	0.01; l²=84%					
Bile Duct Injury, n 5,18						
Subtotal	27138	266735	OR: 0.42 [0.13 ; 1.38]	p=0.15		
Random, Heterogeneity: p<0).01; l²=92%					
Readmissions 30-day, n 4,5	i					
Subtotal	2737	2737	OR: 0.55 [0.29 ; 1.05]	p=0.07		
Random, Heterogeneity: p<0).01; I²=93%					
Reoperations 30-day, n 4,5						
Subtotal	2737	2737	OR: 0.75 [0.53 ; 1.07]	p=0.11		
Fixed, Heterogeneity: p=0.55	5; I²=0%					

INTUÎTIVE

Robotic-assisted vs. laparoscopic cholecystectomy

Weighted estimates based on 31 studies

Meta-analysis covering period January 1, 2010 – April 15, 2024

This study analyzed continuous variables using weighted means and categorical variables using weighted rates with fixed or random effects models. This method gives more influence to studies with higher weights, providing a more accurate estimate of central tendency when combining results from multiple studies.

Outcomes
that favor
RAS

Conversions2.6% vs 6.3%Estimated
blood loss14.8 ml vs 22.5 ml

Comparable outcomes

Blood transfusions	1.9% vs 1.9%
Bile duct leak	1.5% vs 0.6%
Bile duct injury	0.7% vs 0.5%
Bile duct obstruction	0.7% vs 0.7%
Surgical site infection	1.3% vs 1.3%
Length of hospital stay	2.0 days vs 2.3 days
Length of hospital stay 30-day postoperative complications	2.0 days vs 2.3 days 13.3% vs 12.0%
Length of hospital stay 30-day postoperative complications 30-day readmissions	2.0 days vs 2.3 days 13.3% vs 12.0% 5.7% vs 5.7%
Length of hospital stay30-day postoperative complications30-day readmissions30-day reoperations	2.0 days vs 2.3 days 13.3% vs 12.0% 5.7% vs 5.7% 1.4% vs 1.4%

Disclaimer: The number of studies used to calculate the weighted estimates for each outcome varies

Outcomes that favor Laparoscopic

Operative time 97.0 min vs 87.1 min

Robotic-assisted vs. open cholecystectomy

Weighted estimates based on 3 studies

Meta-analysis covering period January 1, 2010 – April 15, 2024

This study analyzed continuous variables using weighted means and categorical variables using weighted rates with fixed or random effects models. This method gives more influence to studies with higher weights, providing a more accurate estimate of central tendency when combining results from multiple studies.

Outcomes that favor RAS

Surgical site infection	2.1% vs 7.0%
Blood transfusion	3.4% vs 8.9%
Length of stay	3.0 days vs 6.5 days
30-day postoperative complications	19.8% vs 30.8%
30-day mortality	4.3% vs 8.2%

Comparable outcomes

Bile duct injury	0.7% vs 2.0%
30-day readmissions	10.5% vs 18.7%
30-day reoperations	2.3% vs 3.1%

Outcomes that favor Open

Disclaimer: The number of studies used to calculate the weighted estimates for each outcome varies

Cholecystectomy: bibliography April 15, 2024

- 1. Aguayo, E., Dobaria, V., Nakhla, M., Seo, Y. J., Hadaya, J., Cho, N. Y., . . . Benharash, P. (2020). National trends and outcomes of inpatient robotic-assisted versus laparoscopic cholecystectomy. [2c]. Surgery (United States), 168(4), 625-630. doi:10.1016/j.surg.2020.06.018
- Altieri, M. S., Yang, J., Telem, D. A., Zhu, J., Halbert, C., Talamini, M., & Pryor, A. D. (2016). Robotic approaches may offer benefit in colorectal procedures, more controversial in other areas: a review of 168,248 cases. [2c]. Surgical Endoscopy, 30(3), 925-933. doi:10.1007/s00464-015-4327-2
- Ayloo, S.-.-R., Y.-//-Choudhury, N. (2014). Laparoscopic versus robot-assisted cholecystectomy: A retrospective cohort study. [3b]. Int J Surg, 12(10), 1077-1081. doi:10.1016/j.ijsu.2014.08.405
- Aziz, H.-.-Z., M.-//-Kaur, N.-//-Emamaullee, J.-//-Ahearn, A.-//-Kulkarni, S.-//-Genyk, Y.-//-Selby, R. R.-//-Sheikh, M. R. (2020). A Potential Role for Robotic Cholecystectomy in Patients with Advanced Liver Disease: Analysis of the NSQIP Database. [2c]. The American surgeon, 86(4), 341-345. Retrieved from <u>http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L631717562-//-</u> https://www.ingentaconnect.com/content/sesc/tas/2020/00000086/00000004/art00030;isessionid=11f9iei97qgam.x-ic-live-02
- Campbell, S.-.-L., S. H.-//-Liu, Y.-//-Wren, S. M. (2023). A retrospective study of laparoscopic, robotic-assisted, and open emergent/urgent cholecystectomy based on the PINC AI Healthcare Database 2017-2020. [2c]. World J Emerg Surg, 18(1), 55. doi:10.1186/s13017-023-00521-8
- Chen, H. A.--H., Z.-//-Moushey, A. M.-//-Diab, N. S.-//-Mehta, S. K.-//-Corey, B. (2022). Robotic Cholecystectomies: What are They Good for? - A Retrospective Study - Robotic versus Conventional Cases. [3b]. J Surg Res, 278, 350-355. doi:10.1016/j.jss.2022.04.074
- Cho, G., Yoo, T., & Chang, W. (2022). Robotic cholecystectomy with a new port placement: Is it really beneficial? [2b]. Asian Journal of Surgery, 45(8), 1542-1546. doi:10.1016/j.asjsur.2021.09.016
- Corzo, M. P.--T., D.-//-Martinino, A.-//-Secchi, R.-//-Elzein, S.-//-Lee, Y. K.-//-Abou-Mrad, A.-//-Oviedo, R. J. (2024). Feasibility of robotic cholecystectomy at an academic center with a young robotic surgery program: a retrospective cohort study with umbrella review. [3b]. J Robot Surg, 18(1), 93. doi:10.1007/s11701-024-01824-x
- Eid, J. J., Jyot, A., Macedo, F. I., Sabir, M., & Mittal, V. K. (2020). Robotic Cholecystectomy Is a Safe Educational Alternative to Laparoscopic Cholecystectomy During General Surgical Training: A Pilot Study. [3b]. J Surg Educ, 77(5), 1266-1270. doi:10.1016/j.jsurg.2020.02.027
- Gangemi, A., Danilkowicz, R., Elli, F. E., Bianco, F., Masrur, M., & Giulianotti, P. C. (2017). Could ICG-aided robotic cholecystectomy reduce the rate of open conversion reported with laparoscopic approach? A head to head comparison of the largest single institution studies. [3b]. J Robot Surg, 11(1), 77-82. doi:10.1007/s11701-016-0624-6
- Gantschnigg, A.-.-K., O. O.-//-Singhartinger, F.-//-Tschann, P.-//-Hitzl, W.-//-Emmanuel, K.-//-Presl, J. (2023). Short-term outcomes and costs analysis of robotic-assisted versus laparoscopic cholecystectomy—a retrospective single-center analysis. [3b]. Langenbeck's Archives of Surgery, 408(1). doi:10.1007/s00423-023-03037-6
- 12. Greenberg, S., Abou Assali, M., Li, Y., Bossie, H., Neighorn, C., Wu, E., & Mukherjee, K. (2024). ROBOtic Care Outcomes Project for acute gallbladder pathology. [2c from 3b]. J Trauma Acute Care Surg, 96(6), 971-979. doi:10.1097/ta.0000000004240
- Grimsley, E. A.-,-J., H. M.-//-Herron, T.-//-Read, M. D.-//-Lorch, S.-//-Cha, J. Y.-//-Farach, S. M.-//-Douglas, G. P.-//-Kuo, P. C. (2023). Patient outcomes and cost in robotic emergency general surgery. [2c]. J Robot Surg, 17(6), 2937-2944. doi:10.1007/s11701-023-01739-z
- 14. Hawasli, A., Sahly, M., Meguid, A., Edhayan, E., Guiao, C., & Szpunar, S. (2016). The impact of robotic cholecystectomy on private practice in a community teaching hospital. [3b]. Am J Surg, 211(3), 610-614. doi:10.1016/j.amjsurg.2015.11.010
- Higgins, R. M.-.-F., M. J.-//-Bosler, M. E.-//-Gould, J. C. (2016). Cost analysis of robotic versus laparoscopic general surgery procedures. [3b]. Surgical Endoscopy and Other Interventional Techniques, 31(1), 1-8. doi:10.1007/s00464-016-4954-2
- Hoffman, A. B.--M., A. A.-//-Towle-Miller, L. M.-//-Karim, S. A.-//-Train, A. T.-//-Burstein, M.-//-Schwaitzberg, S. D.-//-Noyes, K. (2021). The Early (2009-2017) Experience With Robot-assisted Cholecystectomy in New York State. [2c]. Ann Surg, 274(3), e245-e252. doi:10.1097/sla.00000000004932

- Juza, R. M., Haluck, R. S., Won, E. J., Enomoto, L. M., Pauli, E. M., Rogers, A. M., . . . Lyn-Sue, J. R. (2014). Training current and future robotic surgeons simultaneously: initial experiences with safety and efficiency. [3b]. J Robot Surg, 8(3), 227-231. doi:10.1007/s11701-014-0455-2
- Kalata, S., Thumma, J. R., Norton, E. C., Dimick, J. B., & Sheetz, K. H. (2023). Comparative Safety of Robotic-Assisted vs Laparoscopic Cholecystectomy. [2c]. JAMA Surg, 158(12), 1303-1310. doi:10.1001/jamasurg.2023.4389
- Kaminski, J. P., Bueltmann, K. W., & Rudnicki, M. (2014). Robotic versus laparoscopic cholecystectomy inpatient analysis: does the end justify the means? [2c]. Journal of Gastrointestinal Surgery, 18(12), 2116-2122. doi:10.1007/s11605-014-2673-3
- Kane, W. J., Charles, E. J., Mehaffey, J. H., Hawkins, R. B., Meneses, K. B., Tache-Leon, C. A., & Yang, Z. (2020). Robotic compared with laparoscopic cholecystectomy: A propensity matched analysis. [3b]. Surgery (United States), 167(2), 432-435. doi:10.1016/j.surg.2019.07.020
- Khorgami, Z., Li, W. T., Jackson, T. N., Howard, C. A., & Sclabas, G. M. (2019). The cost of robotics: an analysis of the added costs of robotic-assisted versus laparoscopic surgery using the National Inpatient Sample. [2c]. Surgical Endoscopy, 33(7), 2217-2221. doi:10.1007/s00464-018-6507-3
- Lunardi, N.-.-A.-Z., A.-//-Florecki, K. L.-//-Chidambaram, S.-//-Shih, I. F.-//-Kent, A. J.-//-Joseph, B.-//-Byrne, J. P.-//-Sakran, J. V. (2024). Robotic Technology in Emergency General Surgery Cases in the Era of Minimally Invasive Surgery. [2c]. JAMA surgery, 159(5), 493-499. doi:10.1001/jamasurg.2024.0016
- Mehaffey, J. H.-.-M., A. D.-//-Mullen, M. G.-//-Yount, K. W.-//-Meneveau, M. O.-//-Smith, P. W.-//-Friel, C. M.-//-Schirmer, B. D. (2017). Adoption of robotics in a general surgery residency program: at what cost? [3b]. Journal of Surgical Research, 213, 269-273. doi:10.1016/j.jss.2017.02.052
- Ng, A. P.-.-S., Y.-//-Bakhtiyar, S. S.-//-Ebrahimian, S.-//-Branche, C.-//-Benharash, P. (2023). National analysis of cost disparities in roboticassisted versus laparoscopic abdominal operations. [2c]. Surgery, 173(6), 1340-1345. doi:10.1016/j.surg.2023.02.016
- Pokala, B., Flores, L., Armijo, P. R., Kothari, V., & Oleynikov, D. (2019). Robot-assisted cholecystectomy is a safe but costly approach: A national database review. [2c]. American Journal of Surgery, 218(6), 1213-1218. doi:10.1016/j.amjsurg.2019.08.014
- Rifai, A. O., Rembetski, E. M., Stutts, L. C., Mazurek, Z. D., Yeh, J. L., Rifai, K., ... Rydell, D. J. (2023). Retrospective analysis of operative time and time to discharge for laparoscopic vs robotic approaches to appendectomy and cholecystectomy. [3b]. J Robot Surg, 17(5), 2187-2193. doi:10.1007/s11701-023-01632-9
- Salman, M. B., T.; Martin, J.; Bhuva, K.; Grim, R.; Ahuja, V. (2013). Use, Cost, Complications, and Mortality of Robotic versus Nonrobotic General Surgery Procedures Based on a Nationwide Database. [2c]. Am Surg, 79(6), 553-560. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23711262
- Sharma, S.-.-H., R.-//-Hui, S.-//-Smith, M. C.-//-Chung, P. J.-//-Schwartzman, A.-//-Sugiyama, G. (2018). The utilization of fluorescent cholangiography during robotic cholecystectomy at an inner-city academic medical center. [3b]. J Robot Surg, 12(3), 481-485. doi:10.1007/s11701-017-0769-y
- Shenoy, R., Mederos, M. A., Jacob, R. L., Kondo, K. K., DeVirgilio, M., Ward, R., . . . Hynes, D. M. (2022). Robot-Assisted General Surgery Procedures at the Veterans Health Administration: A Comparison of Surgical Techniques. [2c]. Journal of Surgical Research, 279, 330-337. doi:10.1016/j.jss.2022.06.032
- Strosberg, D. S., Nguyen, M. C., Muscarella, P., 2nd, & Narula, V. K. (2017). A retrospective comparison of robotic cholecystectomy versus laparoscopic cholecystectomy: operative outcomes and cost analysis. [3b]. Surg Endosc, 31(3), 1436-1441. doi:10.1007/s00464-016-5134-0
- Tao, Z., Emuakhagbon, V. S., Pham, T., Augustine, M. M., Guzzetta, A., & Huerta, S. (2021). Outcomes of robotic and laparoscopic cholecystectomy for benign gallbladder disease in Veteran patients. [3b]. J Robot Surg, 15(6), 849-857. doi:10.1007/s11701-020-01183-3

Disclosures

Important Safety Information

(US) Serious complications may occur in any surgery, including da Vinci surgery, up to and including death. Serious risks include, but are not limited to, injury to tissues and organs and conversion to other surgical techniques which could result in a longer operative time and/or increased complications. For summary of the risks associated with surgery refer to www.intuitive.com/safety.

Da Vinci Xi®/da Vinci X® system precaution statement

The demonstration of safety and effectiveness for the representative specific procedures did not include evaluation of outcomes related to the treatment of cancer (overall survival, disease-free survival, local recurrence), except for radical prostatectomy which was evaluated for overall survival, or treatment of the patient's underlying disease/condition. Device usage in all surgical procedures should be guided by the clinical judgment of an adequately trained surgeon.

(EU) Medical devices, CE 2460, refer to Instructions For Use for further information.

For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, refer to the associated user manual(s) or visit https://manuals.intuitivesurgical.com/market.

Some products, features or technologies may not be available in all countries. Please contact your local Intuitive representative for product availability in your region.

Individual outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics, and/or surgeon experience.

<u>Privacy Notice</u>: Intuitive's Privacy Notice is available at www.intuitive.com/privacy.

© 2024 Intuitive Surgical Operations, Inc. All rights reserved. Product and brand names/logos are trademarks or registered trademarks of Intuitive Surgical or their respective owner.

INTUITIVE

intuitive.com